150 related articles for article (PubMed ID: 22616988)
1. MF101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms.
Leitman DC; Christians U
Expert Opin Investig Drugs; 2012 Jul; 21(7):1031-42. PubMed ID: 22616988
[TBL] [Abstract][Full Text] [Related]
2. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.
Stovall DW; Pinkerton JV
Curr Opin Investig Drugs; 2009 Apr; 10(4):365-71. PubMed ID: 19337958
[TBL] [Abstract][Full Text] [Related]
3. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial.
Grady D; Sawaya GF; Johnson KC; Koltun W; Hess R; Vittinghoff E; Kristof M; Tagliaferri M; Cohen I; Ensrud KE
Menopause; 2009; 16(3):458-65. PubMed ID: 19182698
[TBL] [Abstract][Full Text] [Related]
4. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract.
Cvoro A; Paruthiyil S; Jones JO; Tzagarakis-Foster C; Clegg NJ; Tatomer D; Medina RT; Tagliaferri M; Schaufele F; Scanlan TS; Diamond MI; Cohen I; Leitman DC
Endocrinology; 2007 Feb; 148(2):538-47. PubMed ID: 17095596
[TBL] [Abstract][Full Text] [Related]
5. Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101.
Tagliaferri M; Creasman J; Caygill KA; Olyaie A; Leitman D; Cohen I; Grady D
Climacteric; 2012 Dec; 15(6):607-10. PubMed ID: 22257013
[TBL] [Abstract][Full Text] [Related]
6. Emerging hormonal treatments for menopausal symptoms.
Genazzani AR; Komm BS; Pickar JH
Expert Opin Emerg Drugs; 2015 Mar; 20(1):31-46. PubMed ID: 25557757
[TBL] [Abstract][Full Text] [Related]
7. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
Pickar JH; Mirkin S
Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
[TBL] [Abstract][Full Text] [Related]
8. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms.
Stovall DW
Curr Opin Investig Drugs; 2010 Apr; 11(4):464-71. PubMed ID: 20336595
[TBL] [Abstract][Full Text] [Related]
9. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist.
Mersereau JE; Levy N; Staub RE; Baggett S; Zogovic T; Chow S; Ricke WA; Tagliaferri M; Cohen I; Bjeldanes LF; Leitman DC
Mol Cell Endocrinol; 2008 Feb; 283(1-2):49-57. PubMed ID: 18177995
[TBL] [Abstract][Full Text] [Related]
10. Effective herbal treatment of vasomotor symptoms--are we any closer?
Kaunitz AM
Menopause; 2009; 16(3):428-9. PubMed ID: 19169160
[No Abstract] [Full Text] [Related]
11. Isoflavones and women's health.
Powles T
Breast Cancer Res; 2004; 6(3):140-2. PubMed ID: 15084236
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.
Rossouw JE; Manson JE; Kaunitz AM; Anderson GL
Obstet Gynecol; 2013 Jan; 121(1):172-6. PubMed ID: 23262943
[TBL] [Abstract][Full Text] [Related]
13. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Pinkerton JV; Pickar JH; Racketa J; Mirkin S
Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
[TBL] [Abstract][Full Text] [Related]
14. Treatment of menopausal vasomotor symptoms.
Med Lett Drugs Ther; 2004 Dec 6-20; 47(1197-1198):98-9. PubMed ID: 15583526
[TBL] [Abstract][Full Text] [Related]
15. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
Pinkerton JV; Stovall DW
Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
[TBL] [Abstract][Full Text] [Related]
16. Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.
Stovall DW; Tanner-Kurtz K; Pinkerton JV
Drugs; 2011 Sep; 71(13):1649-57. PubMed ID: 21902289
[TBL] [Abstract][Full Text] [Related]
17. Tissue-selective Estrogen Complex for Menopausal Hormone Therapy.
Pinkerton JV
Clin Obstet Gynecol; 2018 Sep; 61(3):463-469. PubMed ID: 29851863
[TBL] [Abstract][Full Text] [Related]
18. Undertreatment of menopausal symptoms and novel options for comprehensive management.
Lewis V
Curr Med Res Opin; 2009 Nov; 25(11):2689-98. PubMed ID: 19775194
[TBL] [Abstract][Full Text] [Related]
19. Advances in menopausal therapy: the tissue-selective estrogen complex.
Moore A
J Am Assoc Nurse Pract; 2013 Mar; 25(3):126-33. PubMed ID: 24218199
[TBL] [Abstract][Full Text] [Related]
20. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
